- Medicine - Nov 21 MVLS academics named as Highly Cited Researchers
- Medicine - Nov 21 Four Queen Mary University of London scientists make Highly Cited Researchers 2014 List
- Life Sciences - Nov 21 Report highlights opportunities and risks associated with synthetic biology and bioengineering
- Administration - Nov 21 Worldwide campaign on abortion raises $300m, UCL Lancet lecture told
- Medicine - Nov 20 Systems of change behind everything from climate to health
- Medicine - Nov 20 Young people have more varied sex lives than their parents
- Medicine - Nov 17 Foodbank users report benefit delays, adverse life events
- Physics - Nov 17 Controlling growth of organic crystals with high- powered magnets could have major benefits for pharmaceutical development
- Medicine - Nov 17 UofG signs historic agreement with Thailand’s Mahidol University
- Life Sciences - Nov 17 Puppy poo needed to monitor antibiotic- resistant bacteria
- Medicine - Nov 16 From Hong Kong high- rise to world- leading renal researcher
- Medicine - Nov 16 New talking therapy could help cancer survivors cope after treatment
Ebola vaccine offers long-lasting immunity
An Ebola vaccine has been shown to provide immunity for up to a year after immunisation in all of those immunised in a new study.
The findings, based on a Phase 1 clinical trial involving 75 healthy subjects, were published in the Journal of the American Medical Association (JAMA).
The study was led by the Oxford Vaccine Group at the University of Oxford. It tested the prime-boost Ebola vaccine regimen being developed by Janssen Vaccines & Prevention B.V. that is based on Janssen’s AdVac technology and MVA-BN technology from Bavarian Nordic A/S. Healthy volunteers were given one vaccine dose to prime their immune system, and the alternative vaccine to boost their immune response. Additional Phase 1, 2 and 3 studies are ongoing to build on these findings.
This is the longest duration follow-up for any heterologous prime-boost Ebola vaccine regimen yet published.
Dr Matthew Snape from the Department of Paediatrics at Oxford, who led the research, said: ’The persistence of vaccine-induced immunity to one year post-immunisation is truly impressive.
’The fact that all participants retained Ebola-specific antibodies to the end of the study does raise hope that this vaccine could induce responses that last for several years.
’This study was conducted in a European population, so it’s important to note that immune responses may differ in a sub-Saharan African population, but these vaccine candidates are currently being assessed in this region.
’Additional research is also needed to explore the persistence of immunity beyond the one year mark and the response to booster doses of vaccine.’
A total of ten clinical studies are being conducted on a parallel track across the US, Europe and Africa in support of potential eventual registration for the Ebola vaccine regimen. The first study of the vaccine regimen in a West African country affected by the recent Ebola outbreak began in Sierra Leone in October 2015.
The full research letter, - Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Ankara-Vectored Ebola Vaccines at 1 Year ,’ can be read in JAMA.
Last job offers
- Medicine/Pharmacology - 17.11
Nuffield Professorship of Clinical Medicine
- Medicine/Pharmacology - 14.11
Chair in Healthcare Management
- Medicine/Pharmacology - 8.11
Lecturer (Assistant Professor) / Senior Lecturer (Associate Professor)
- Medicine/Pharmacology - 7.11
Associate Professor in Pharmacy Practice
- Medicine/Pharmacology - 6.11
Professor and Honorary Consultant in Anaesthesia and Perioperative Medicine
- Medicine/Pharmacology - 2.11
Associate Professor of Nursing
- Medicine/Pharmacology - 2.11
Associate Professor of Midwifery
- Medicine/Pharmacology - 27.10
Professor and Director, UCL Institute for Women’s Health